German drug company Merck KGaA said Monday it has struck a deal to buy U.S. biotech firm SpringWorks Therapeutics for around ...

Merck KGaA acquires SpringWorks Therapeutics for $3.9B to enhance its cancer drug portfolio, boosting revenue growth and ...

Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 ...

Germany’s Merck KGaA agreed to acquire U.S. biopharmaceutical company SpringWorks Therapeutics for around $3.9 billion, in a ...

Germany’s Merck KGaA has agreed to acquire U.S. biotech SpringWorks Therapeutics for $3.9 billion. The acquisition, aimed at ...

Merck KGaA acquires SpringWorks Therapeutics, Inc. for $3.9B, boosting its pipeline with OGSIVEO & GOMEKLI. Click for more on ...

对于此次收购，德国默克执行董事会主席兼首席执行官 Belén Garijo 表示：“SpringWorks ...

在全球生物技术行业不断变革的背景下，德国医疗保健和材料集团默克（Merck KGaA）近日宣布以39亿美元的股权价值收购美国生物技术公司SpringWorks Therapeutics的消息，引发了广泛关注。这一交易不仅展示了默克在抗癌药物领域的雄心 ...

Merck KGaA said the deal will grow its U.S. presence and expand the reach of SpringWorks’ drugs, including one approved in February.

SpringWorks总部位于美国康涅狄格州的斯坦福德，于2019年在纽约上市。该公司开发治疗癌症和罕见肿瘤的药物，目前在市场上有两种产品：用于治疗硬纤维瘤的Ogsiveo，2024年销售额为1.72亿美元，以及Gomekli，今年2月获批用于治疗以 ...

Germany's Merck KGaA said on Thursday it is in late-stage talks to acquire U.S.-based SpringWorks Therapeutics for about $3.5 ...

Merck KGaA is nearing a deal to acquire SpringWorks Therapeutics Inc., people familiar with the matter said. An announcement ...